Retrospective Study on the Effectiveness and Safety of Baricitinib in Treating Alopecia Areata

In this study, ritlecitinib treatment for 12 and 24 weeks downregulated immunity-related genes and upregulated hair keratin genes in patients with alopecia areata, correlating with scalp hair regrowth response.

In this study at Tohoku University Hospital, 41% of severe alopecia areata patients achieved significant hair regrowth with baricitinib treatment over 9 months, with predictors of better outcomes including shorter disease duration, female sex, initial mild disease, certain alopecia types, and prior IVMP therapy.

This study identified multiple factors affecting the severity of alopecia areata, suggesting they could inform a tool for measuring disease impact and guide treatment selection.

This consensus statement outlines a treatment algorithm for alopecia areata, detailing systemic treatment indications and options, including EMA-approved medications baricitinib and ritlecitinib for severe cases, as well as other off-label treatments and adjuvant therapies like oral minoxidil.

In this study, researchers identified subgroups of patients with severe alopecia areata treated with baricitinib who experienced early, gradual, or late hair regrowth, finding that response was influenced by baseline disease severity and duration of hair loss.

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

This review highlights the significant negative impact of alopecia areata on quality of life, mental health, and work, calling for individualized approaches and effective treatments to mitigate these effects.

This review discusses the challenges in identifying specific hair follicle antigens involved in initiating alopecia areata and highlights the need for further research to understand its etiopathogenesis, reporting no new results.

This study observed that both ritlecitinib and brepocitinib improved scalp biomarkers in patients with alopecia areata, with associations to hair regrowth seen in this phase 2a trial.

This study found that alopecia areata is linked with a higher prevalence of systemic and psychiatric diseases, suggesting that physicians should monitor for these potential comorbidities.